Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,750 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depression Severe Clear all
Completed No phase listed Observational Accepts healthy volunteers

Neurocognitive Outcomes of Depression in the Elderly

NCT00570583
View directory record Official record
Conditions
Major Depression, Dementia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 17, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

NCT04634669
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05 (dextromethorphan-bupropion)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

NCT01254305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study

NCT02158546
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
50
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 17, 2026, 11:12 PM EDT
Terminated Phase 2Phase 3 Interventional

SAINT for MDD in an Inpatient Setting Follow-on

NCT06462820
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
Interventions
Active SAINT Stimulation, Sham SAINT Stimulation
Device
Lead sponsor
Magnus Medical
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Iowa City, Iowa • Manhattan, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 4 Interventional

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

NCT00021528
View directory record Official record
Conditions
Depression
Interventions
citalopram, BuproprionSR, buspirone, Lithium, mirtazapine, nortriptyline, sertraline, tranylcypromine, VenlafaxineXR, Cognitive Therapy, T3 (Triiodothyronine)
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Chula Vista, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

NCT00671515
View directory record Official record
Conditions
Depressive Disorder, Major, Metabolic Syndrome X
Interventions
Pioglitazone
Drug
Lead sponsor
Joseph Calabrese, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00296725
View directory record Official record
Conditions
Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
Interventions
Fluoxetine, Imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 17, 2026, 11:12 PM EDT
Completed No phase listed Observational

The Treatment of Children and Adolescents With Treatment-Resistant Depression

NCT00029640
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 11:12 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Sensory Synchronized Imaging and Neuromodulation

NCT06548113
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TMS
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 11:12 PM EDT
Recruiting Phase 1 Interventional

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

NCT05915013
View directory record Official record
Conditions
Depressive Disorder, Major, Post Traumatic Stress Disorder
Interventions
Ketamine, Perampanel, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 11:12 PM EDT
Completed No phase listed Observational

Phenotype Depression Study

NCT01426997
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Not applicable Interventional

Comparing Engage to PST for Late Life Depression

NCT02086201
View directory record Official record
Conditions
Major Depression
Interventions
Problem Solving Therapy, Engage
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
60 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
White Plains, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Results available

Lipopolysaccharide (LPS) Challenge in Depression

NCT03142919
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lipopolysaccharide, Placebo
Biological
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
9 Years to 17 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
18
States / cities
Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Not applicable Interventional

Computerized Cognitive Behavior Therapy in Treating Depression in Patients With Cancer

NCT02837887
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Computerized Cognitive Behavior Therapy
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 17, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional

Digital Intervention for Physical Activity

NCT07130734
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Anxiety, Stress
Interventions
Digital Physical Activity
Behavioral
Lead sponsor
Auburn University
Other
Eligibility
19 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

Naltrexone for Antipsychotic-Induced Weight Gain

NCT01866098
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Severe Major Depression With Psychotic Features
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

NCT00411099
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
42
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Cerritos, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Results available

Abilify as an Adjunctive Treatment for Refractory Depression

NCT00220636
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Aripiprazole
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 17, 2026, 11:12 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Pregnenolone for Cannabis Use Disorder and Depression

NCT07685964
View directory record Official record
Conditions
Cannabis Use Disorder, Major Depressive Disorder (MDD)
Interventions
Pregnenolone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Results available

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

NCT00845507
View directory record Official record
Conditions
Weight Gain
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 17, 2026, 11:12 PM EDT
Completed Phase 2 Interventional

A Study of Intermittent Doses of CERC-301 in MDD

NCT02459236
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CERC-301, Placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Newport Beach, California • Alpharetta, Georgia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 17, 2026, 11:12 PM EDT
Withdrawn No phase listed Observational

Using EEG to Predict Depression Treatment Response to rTMS in Patients With Major Depression

NCT04575285
View directory record Official record
Conditions
Major Depression, Repetitive Transcranial Magnetic Stimulation
Interventions
Electroencephalogram (EEG)
Diagnostic Test
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 17, 2026, 11:12 PM EDT